Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous sHIV challenge

Kier Om, Dominic Paquin-Proulx, Maria Montero, Kristina Peachman, Xiaoying Shen, Lindsay Wieczorek, Zoltan Beck, Joshua A. Weiner, Dohoon Kim, Yifan Li, Thembi Mdluli, Zhanna Shubin, Christopher Bryant, Vishakha Sharma, Andrey Tokarev, Peter Dawson, Yohann White, Oliver Appelbe, Nichole R. Klatt, Sodsai TovanabutraJacob D. Estes, Gary R. Matyas, Guido Ferrari, Carl R. Alving, Georgia D. Tomaras, Margaret E. Ackerman, Nelson L. Michael, Merlin L. Robb, Victoria Polonis, Morgane Rolland, Michael A. Eller, Mangala Rao, Diane L. Bolton*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env gp145 was evaluated in macaques with either aluminum (alum) or a novel liposomal monophosphoryl lipid A (MPLA) formulation adsorbed to alum, ALFA. Binding antibody responses were robust and comparable between arms, while antibody-dependent neutrophil and monocyte phagocytotic responses were greatly enhanced by ALFA. Per-exposure vaccine efficacy against heterologous tier 2 SHIV mucosal challenge was 90% in ALFA-adjuvanted males (P = 0.002), while alum conferred no protection. Half of the ALFA-adjuvanted males remained uninfected after the full challenge series, which spanned seven months after the last vaccination. Antibody-dependent monocyte and neutrophil phagocytic responses both strongly correlated with protection. Significant sex differences in infection risk were observed, with much lower infection rates in females than males. In humans, MPLA-liposome-alum adjuvanted gp120 also increased HIV-1-specific phagocytic responses relative to alum. Thus, next-generation liposome-based adjuvants can drive vaccine elicited antibody effector activity towards potent phagocytic responses in both macaques and humans and these responses correlate with protection. Future protein vaccination strategies aiming to improve functional humoral responses may benefit from such adjuvants.

Original languageEnglish
Article numbere1008764
JournalPLoS Pathogens
Issue number9
StatePublished - Sep 2020
Externally publishedYes


Dive into the research topics of 'Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous sHIV challenge'. Together they form a unique fingerprint.

Cite this